Report #2838202

Received Apr 28, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: —
Recovered: Unknown
Vaccinated: —
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
PNC21	PNEUMO (CAPVAXIVE)	MERCK & CO. INC.	UNK	—	—

Symptoms (1)

Product administered to patient of inappropriate age

Symptom narrative

They administered the product PCV-21/capvaxive to a baby.; Capvaxive, was being labeled as Prevnar 21.; This spontaneous report was received from a consumer or other non-health professional, via Pfizer and refers to an infant patient (reported as baby) of unknown gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On an unknown date, the patient was vaccinated with Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE) (dose, dose number, frequency, vaccination scheme, anatomical location, route of administration, lot number, expiration date was not provided) as prophylaxis (product administered to patient of inappropriate age). Caller reported that Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE) was being labeled as Prevnar 21 (product label issue).